GSK's former head of vaccines R&D – Dr Emmanuel Hanon – is heading up a new biotech called Vicebio that will go up against his former employer with a vaccine against respiratory syncytial virus (RSV) ...
A new version has now started testing, while GSK has also focused on providing its adjuvant technology to other developers like South Korea's SK bio. In the midst of that, Hanon left GSK in April ...
Learn the benefits and risks of options and how to start trading options Lucas Downey is the co-founder of MoneyFlows, and an Investopedia Academy instructor. Samantha (Sam) Silberstein, CFP®, CSLP®, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results